Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 6Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 25Neoplasms 3Neoplasm Metastasis 3Stomach Neoplasms 1Sarcoma 1Osteitis Deformans 1Neoplastic Cells, Circulating 1Invasive Breast Cancer 1Head and Neck Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER2 Positive Metastatic Breast Cancer 1Esophageal Neoplasms 1Carcinoma 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

exemestane 4Tamoxifen 3Paclitaxel 3Letrozole 3Goserelin 3Cyclophosphamide 3pegfilgrastim 2Radiotherapy 2Pyridoxine 2Leuprolide 2Fluorouracil 2Epirubicin 2Capecitabine 2Bevacizumab 2Anastrozole 2trastuzumab biosimilar HLX02 1ribociclib 1elacestrant 1Zoledronic Acid 1Trastuzumab 1Taxes 1Radiosurgery 1Prochlorperazine 1Palonosetron 1PF-05280014 1Ontruzant 1Ogivri 1Neoadjuvant Therapy 1Mometasone Furoate 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms, Male × Lapatinib × Clear all
NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 3 Completed
305 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡